Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UC

被引：0
|
作者：
Peyrin-Biroulet, L. [1 ]
Yen, M. [2 ]
Zhou, W. [2 ]
Dong, B. [2 ]
Danese, S. [3 ]
Feagan, B. G. [4 ,5 ]
Sands, B. E. [6 ]
机构：
[1] CHRU Nancy, INFINY Inst, Dept Gastroenterol, INSERM,NGERE, Nancy, France
[2] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Gastroenterol & Gastrointestinal Endoscopy Unit, Milan, Italy
[4] Western Univ, Dept Med Epidemiol, London, ON, Canada
[5] Western Univ, Dept Biostat, London, ON, Canada
[6] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1259
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1085
引用
收藏
页码：i1997 / i1998
页数：2
相关论文
共 42 条
  • [1] RELATIONSHIP BETWEEN SYMPTOM RESOLUTION AND CLINICAL RESPONSES AFTER 12 WEEKS OF TREATMENT WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM ARTEMIS-UC
    Ma, Christopher
    Boland, Brigid
    Leong, Rupert W.
    Horynski, Marek
    Yen, Mark
    Lu, J. D.
    Luo, Allison
    GASTROENTEROLOGY, 2024, 166 (05) : S807 - S807
  • [2] Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis
    Panes, Julian
    Su, Chinyu
    Marren, Amy
    Yu, Dahong
    Woodworth, Deborah A.
    Zhang, Haiying
    Healey, Paul J.
    GASTROENTEROLOGY, 2016, 150 (04) : S1003 - S1003
  • [3] EFFECT OF RISANKIZUMAB ON EARLY SYMPTOMS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF THE INSPIRE INDUCTION STUDY
    Siegel, Corey A.
    Rubin, David T.
    Panaccione, Remo
    Rieder, Florian
    Takeuchi, Ken
    Hecht, Patrick
    Levine, Phillip
    Gonzalez, Yuri Sanchez
    Zhang, Yafei
    Vladea, Ramona C.
    Biedermann, Luc
    Wu, Kaichun
    GASTROENTEROLOGY, 2024, 166 (05) : S805 - S805
  • [4] Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis
    Panes, J.
    Su, C.
    Marren, A.
    Yu, D.
    Woodworth, D.
    Zhang, H.
    Healey, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S283 - S284
  • [5] PREDICTIVE VALUE OF PATIENT-REPORTED OUTCOMES TO MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Colombel, J. F.
    Han, C.
    Reinisch, W.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Gibson, P.
    Collins, J.
    Rutgeerts, P.
    Sandborn, W.
    VALUE IN HEALTH, 2014, 17 (03) : A40 - A40
  • [6] Early Responses in Patient-reported Outcomes Are Predictors for Mucosal Healing in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Golimumab: Results from PURSUIT SC Induction
    Sandborn, William
    Reinisch, Walter
    Feagan, Brian
    Marano, Colleen
    Strauss, Richard
    Han, Chenglong
    Johanns, Jewel
    Zhang, Hongyan
    Gibson, Peter
    Collins, Judith
    Jarnerot, Gunnar
    Rutgeerts, Paul
    Colombel, Jean-Frederic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S519 - S519
  • [7] Bowel Urgency and Abdominal Pain in Patients With Moderately to Severely Active Ulcerative Colitis in the Etrasimod ELEVATE UC Clinical Program: A Post Hoc Analysis
    Dubinsky, Marla C.
    Chaparro, Maria
    Armuzzi, Alessandro
    Irving, Peter M.
    Allez, Matthieu
    Panaccione, Remo
    Goetsch, Martina
    Bartolome, Lauren
    Bananis, Eustratios
    Wu, Joseph
    Wosik, Karolina
    Bhattacharjee, Abhishek
    Smith, Christina C.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S889 - S890
  • [8] Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters
    Stallmach, A.
    Bokemeyer, B.
    Axler, J.
    Curtis, R.
    Ehehalt, R.
    Feagan, B.
    Geransar, P.
    James, A.
    Kaviya, A.
    Khalid, J. M.
    Wolf, D.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S42 - S43
  • [9] SUSTAINED REMISSION WITH VEDOLIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A GEMINI 1 POST HOC ANALYSIS OF WEEK 14 REMITTERS
    Bokemeyer, Bernd
    Stallmach, Andreas
    Axler, Jeffrey L.
    Curtis, Rebecca I.
    Ehehalt, Robert
    Schreiber, Stefan
    Geransar, Parnia
    James, Alexandra
    Kaviya, Arpeat
    Khalid, Javaria M.
    Wolf, Douglas C.
    Feagan, Brian G.
    GASTROENTEROLOGY, 2017, 152 (05) : S604 - S604
  • [10] ACHIEVEMENT OF CLINICAL AND ENDOSCOPIC OUTCOMES BY BASELINE CORTICOSTEROID USE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RECEIVED RISANKIZUMAB INDUCTION TREATMENT: A POST-HOC ANALYSIS OF THE INSPIRE STUDY
    Bossuyt, Peter
    Louis, Edouard
    Gecse, Krisztina
    Abreu, Maria T.
    Gionchetti, Paolo
    Rubin, David T.
    Marced, Elena
    Gonzalez, Yuri Sanchez
    Hecht, Patrick
    Kalabic, Jasmina
    Vladea, Ramona C.
    Zhang, Yafei
    Reinisch, Walter
    GASTROENTEROLOGY, 2024, 166 (05) : S806 - S807
12345